244 related articles for article (PubMed ID: 1671782)
1. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
Brücke T; Podreka I; Angelberger P; Wenger S; Topitz A; Küfferle B; Müller C; Deecke L
J Cereb Blood Flow Metab; 1991 Mar; 11(2):220-8. PubMed ID: 1671782
[TBL] [Abstract][Full Text] [Related]
2. Dopamine D2 receptor imaging and measurement with SPECT.
Brücke T; Wenger S; Asenbaum S; Fertl E; Pfafflmeyer N; Müller C; Podreka I; Angelberger P
Adv Neurol; 1993; 60():494-500. PubMed ID: 8420177
[TBL] [Abstract][Full Text] [Related]
3. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease.
Pirker W; Asenbaum S; Wenger S; Kornhuber J; Angelberger P; Deecke L; Podreka I; Brücke T
J Nucl Med; 1997 Nov; 38(11):1711-7. PubMed ID: 9374338
[TBL] [Abstract][Full Text] [Related]
4. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
Reiche W; Grundmann M; Huber G
Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
[TBL] [Abstract][Full Text] [Related]
5. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
[TBL] [Abstract][Full Text] [Related]
6. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
[TBL] [Abstract][Full Text] [Related]
7. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa.
Schwarz J; Oertel WH; Tatsch K
J Nucl Med; 1996 Jul; 37(7):1112-5. PubMed ID: 8965179
[TBL] [Abstract][Full Text] [Related]
8. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H
Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375
[TBL] [Abstract][Full Text] [Related]
10. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W
Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain.
Verhoeff NP; Bobeldijk M; Feenstra MG; Boer GJ; Maas MA; Erdtsieck-Ernste E; de Bruin K; van Royen EA
Int J Rad Appl Instrum B; 1991; 18(8):837-46. PubMed ID: 1839302
[TBL] [Abstract][Full Text] [Related]
13. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease.
Ichise M; Toyama H; Fornazzari L; Ballinger JR; Kirsh JC
J Nucl Med; 1993 Aug; 34(8):1274-81. PubMed ID: 8326384
[TBL] [Abstract][Full Text] [Related]
14. [123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects.
Schlösser R; Schlegel S; Hiemke C; Nickel O; Bockisch A; Rao ML; Hahn K
Psychiatry Res; 1997 Sep; 75(2):103-14. PubMed ID: 9351492
[TBL] [Abstract][Full Text] [Related]
15. IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.
Oertel WH; Schwarz J; Tatsch K; Arnold G; Gasser T; Kirsch CM
Adv Neurol; 1993; 60():519-24. PubMed ID: 8420182
[TBL] [Abstract][Full Text] [Related]
16. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
Pizzolato G; Chierichetti F; Rossato A; Cagnin A; Fabbri M; Dam M; Ferlin G; Battistin L
J Neural Transm Suppl; 1995; 45():113-22. PubMed ID: 8748616
[TBL] [Abstract][Full Text] [Related]
17. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
Schwarz J; Tatsch K; Gasser T; Arnold G; Oertel WH
Mov Disord; 1997 Nov; 12(6):898-902. PubMed ID: 9399212
[TBL] [Abstract][Full Text] [Related]
18. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
[TBL] [Abstract][Full Text] [Related]
19. 123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia.
Berding G; Gratz KF; Kolbe H; Meyer GJ; Dengler R; Knoop BO; Hundeshagen H
Nuklearmedizin; 1994 Oct; 33(5):194-9. PubMed ID: 7997377
[TBL] [Abstract][Full Text] [Related]
20. [Initial experiences with 123-Iodine-IBZM neuroreceptor scintigraphy in extrapyramidal disorders].
Pávics L; Dibó G; Ambrus E; Séra T; Vécsei L; Csernay L
Orv Hetil; 2000 May; 141(20):1073-7. PubMed ID: 10851890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
